Dr Eric O Aboagye

Dr Eric O Aboagye

All Publications

Journals

  • Gray KR; Contractor KB; Kenny LM; Al-Nahhas A; Shousha S; Stebbing J; Wasan HS; Coombes RC; et al. (7 Feb 2010). Kinetic filtering of [(18)F]Fluorothymidine in positron emission tomography studies. Phys Med Biol. 55:695-709. DOI.
  • Pardo OE; Latigo J; Jeffery RE; Nye E; Poulsom R; Spencer-Dene B; Lemoine NR; Stamp GW; et al. (15 Nov 2009). The Fibroblast Growth Factor Receptor Inhibitor PD173074 Blocks Small Cell Lung Cancer Growth In vitro and In vivo. CANCER RES. 69:8645-8651. DOI.
  • Kenny LM; Contractor KB; Stebbing J; Ai-Nahhas A; Palmieri C; Shousha S; Coombes RC; Aboagye EO. (1 Nov 2009). Altered Tissue 3 '-Deoxy-3 '-[F-18]Fluorothymidine Pharmacokinetics in Human Breast Cancer following Capecitabine Treatment Detected by Positron Emission Tomography. CLIN CANCER RES. 15:6649-6657. DOI.
  • Leyton J; Smith G; Zhao YJ; Perumal M; Nguyen QD; Robins E; Arstad E; Aboagye EO. (1 Oct 2009). [F-18]Fluoromethyl-[1,2-H-2(4)]-Choline: A Novel Radiotracer for Imaging Choline Metabolism in Tumors by Positron Emission Tomography. CANCER RES. 69:7721-7728. DOI.
  • Nguyen QD; Smith G; Glaser M; Perumal M; Arstad E; Aboagye EO. (22 Sep 2009). Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide. Proc Natl Acad Sci U S A. 106:16375-16380. DOI.
  • Seckl MJ; Pardo OE; Aboagye EO; Latigo J; Stamp G; Lemoine N; Spencer-Dean B. (Sep 2009). The FGF receptor (FGFR) inhibitor PD0173074 blocks SCLC growth in vitro and in vivo. J THORAC ONCOL. 4:S385-S385.
  • Tennant DA; Frezza C; MacKenzie ED; Nguyen QD; Zheng L; Selak MA; Roberts DL; Dive C; et al. (12 Nov 2009). Reactivating HIF prolyl hydroxylases under hypoxia results in metabolic catastrophe and cell death. Oncogene. 28:4009-4021. DOI.
  • Contractor KB; Kenny LM; Stebbing J; Al-Nahhas A; Palmieri C; Sinnett D; Lewis JS; Hogben K; et al. (1 Sep 2009). [11C]choline positron emission tomography in estrogen receptor-positive breast cancer. Clin Cancer Res. 15:5503-5510. DOI.
  • Ali S; Heathcote DA; Kroll SHB; Jogalekar AS; Scheiper B; Patel H; Brackow J; Siwicka A; et al. (1 Aug 2009). The Development of a Selective Cyclin-Dependent Kinase Inhibitor That Shows Antitumor Activity. CANCER RES. 69:6208-6215. DOI.
  • Smith G; Nguyen QD; Aboagye EO. (1 Sep 2009). Translational Imaging of Apoptosis. Anticancer Agents Med Chem.
  • Contractor KB; Aboagye EO. (May 2009). Monitoring predominantly cytostatic treatment response with 18F-FDG PET. J Nucl Med. 50 Suppl 1:97S-105S. DOI.
  • Rosso L; Brock CS; Gallo JM; Saleem A; Price PM; Turkheimer FE; Aboagye EO. (1 Jan 2009). A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. Cancer Res. 69:120-127. DOI.
  • McParland BJ; Miller MP; Spinks TJ; Kenny LM; Osman S; Khela MK; Aboagye E; Coombes RC; et al. The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers. Journal of Nuclear Medicine. 49:1664-1667.
  • Smith G; Glaser M; Perumal M; Nguyen QD; Shan B; Arstad E; Aboagye EO. (25 Dec 2008). Design, synthesis, and biological characterization of a caspase 3/7 selective isatin labeled with 2-[18F]fluoroethylazide. J Med Chem. 51:8057-8067. DOI.
  • Leyton J; Smith G; Lees M; Perumal M; Nguyen QD; Aigbirhio FI; Golovko O; He Q; et al. (Sep 2008). Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. Mol Cancer Ther. 7:3112-3121. DOI.
  • Chapon C; Jackson JS; Aboagye EO; Herlihy AH; Jones WA; Bhakoo KK. (Jan 2009). An in vivo multimodal imaging study using MRI and PET of stem cell transplantation after myocardial infarction in rats. Mol Imaging Biol. 11:31-38. DOI.
  • Kenny LM; Coombes RC; Oulie I; Contractor KB; Miller M; Spinks TJ; McParland B; Cohen PS; et al. (Jun 2008). Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand F-18-AH111585 in breast cancer patients. J NUCL MED. 49:879-886. DOI.
  • Pillai RG; Forster M; Perumal M; Mitchell F; Leyton J; Aibgirhio FI; Golovko O; Jackman AL; et al. (15 May 2008). Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945. Cancer Res. 68:3827-3834. DOI.
  • Saleem A; Aboagye EO; Matthews JC; Price PM. (Apr 2008). Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes. CANCER CHEMOTH PHARM. 61:865-873. DOI.
  • Leyton J; Aboagye EO. (Dec 2007). PET Tracers as biomarkers in oncology drug development. MOL CANCER THER. 6:3627S-3628S.
  • Chan F; Sun C; Perumal M; Nguyen QD; Bavetsias V; McDonald E; Martins V; Wilsher NE; et al. (Dec 2007). Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. MOL CANCER THER. 6:3147-3157. DOI.
  • McCoy CL; McIntyre DJO; Robinson SP; Aboagye EO; Griffiths JR. (Jul 1996). Magnetic resonance spectroscopy and imaging methods for measuring tumour and tissue oxygenation. BRIT J CANCER. 74:S226-S231.
  • Brown GD; Osman S; Wilson HK; Aboagye E; Price PM; Luthra SK; Brady F. (2001). Metabolism of [11c-Methyl]choline in tumour bearing mice and synthesis and isolation of its catabolite [11c-Methyl]betaine. J Label Compounds Radiopharm.
  • Brown GD; Wilson HK; Westwell AD; Hutchinson I; Stevens MFG; Price PM; Aboagye E; Brady F; et al. (2001). Radiolabelling of the potential anti-cancer agent 5-Fluoro-2-(4-amino-3-methylphenyl)benzothiazole (5F203) with fluorine-18. J Label Compounds Radiopharm.
  • Glaser M; Carroll VA; Collingridge DR; Aboagye E; Price P; Bicknell R; Harris AL; Luthra SK; et al. (2002). Preparation of the iodine-124 derivative of the Bolton-Hunter reagent ({124l}l-SHPP) and its use for labelling a VEGF antibody as a PET tracer. J Labelled Comp Radiopharm. 45:1077-1090.
  • Glaser M; Collingridge DR; Aboagye E; Bouchier-Hayes L; Brown DJ; Hutchinson OC; Martin S; Price PM; et al. (2001). Preparation of [124I]IBA-Annexin-v as a potential PET probe for apoptosis. J Label Compounds Radiopharm.
  • Khanum N; Luthra SK; Zhao Y; Aboagye E; Price PM; Burke P; Brady F. (2001). Carbon-11 labelling of a half mustard prodrug by reductive alkylation using [11C]acetaldehyde. A potential tracer for evolution of ADEPT or GDEPT using PET. J Label Compounds Radiopharm.
  • Aboagye EO. PET imaging of small animals in anticancer drug development. Molecular Imaging in Biology. 7:53-58.
  • Kenny L; Coombes RC; Vigushin DM; Al-Nahhas A; Shousha S; Aboagye EO. (Sep 2007). Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. 34:1339-1347. DOI.
  • Aboagye EO. (Dec 2006). Imaging in drug development. Clin Adv Hematol Oncol. 4:902-904.
  • Leyton J; Lockley M; Aerts JL; Baird SK; Aboagye EO; Lemoine NR; McNeish IA. (15 Sep 2006). Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography imaging. Cancer Res. 66:9178-9185. DOI.
  • Perumal M; Pillai RG; Barthel H; Leyton J; Latigo JR; Forster M; Mitchell F; Jackman AL; et al. (1 Sep 2006). Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Res. 66:8558-8564. DOI.
  • Leyton J; Alao JP; Da Costa M; Stavropoulou AV; Latigo JR; Perumal M; Pillai R; He Q; et al. (1 Aug 2006). In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. Cancer Res. 66:7621-7629. DOI.
  • Gupta N; Saleem A; Kötz B; Osman S; Aboagye EO; Phillips R; Vernon C; Wasan H; et al. (15 May 2006). Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients. Clin Cancer Res. 12:3115-3123. DOI.
  • Workman P; Aboagye EO; Chung YL; Griffiths JR; Hart R; Leach MO; Maxwell RJ; McSheehy PM; et al. (3 May 2006). Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst. 98:580-598. DOI.
  • Kenny LM; Vigushin DM; Al-Nahhas A; Osman S; Luthra SK; Shousha S; Coombes RC; Aboagye EO. (1 Nov 2005). Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res. 65:10104-10112. DOI.
  • Leyton J; Latigo JR; Perumal M; Dhaliwal H; He Q; Aboagye EO. (15 May 2005). Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res. 65:4202-4210. DOI.
  • Buluwela L; Pike J; Mazhar D; Kamalati T; Hart SM; Al-Jehani R; Yahaya H; Patel N; et al. (May 2005). Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-alpha and the transcriptional repressor PLZF. Gene Ther. 12:862. Publisher weblink DOI.
  • Buluwela L; Pike J; Mazhar D; Kamalati T; Hart SM; Al-Jehani R; Yahaya H; Patel N; et al. (Mar 2005). Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-alpha and the transcriptional repressor PLZF. Gene Ther. 12:452-460. DOI.
  • Barthel H; Perumal M; Latigo J; He Q; Brady F; Luthra SK; Price PM; Aboagye EO. (Mar 2005). The uptake of 3'-deoxy-3'-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging. 32:257-263. DOI.
  • Aboagye EO. (Jan 2005). Positron emission tomography imaging of small animals in anticancer drug development. Mol Imaging Biol. 7:53-58. DOI.
  • Sanderson L; Taylor GW; Aboagye EO; Alao JP; Latigo JR; Coombes RC; Vigushin DM. (Oct 2004). Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice. Drug Metab Dispos. 32:1132-1138. DOI.
  • Groot-Wassink T; Aboagye EO; Wang Y; Lemoine NR; Keith WN; Vassaux G. (15 Jul 2004). Noninvasive imaging of the transcriptional activities of human telomerase promoter fragments in mice. Cancer Res. 64:4906-4911. DOI.
  • Barthel H; Wilson H; Collingridge DR; Brown G; Osman S; Luthra SK; Brady F; Workman P; et al. (1 Jun 2004). In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. Br J Cancer. 90:2232-2242. DOI.
  • Malik N; Luthra SK; Burke P; Price PM; Aboagye EO; Latigo J; Zhao Y; Brady F. (Jun 2004). Radiosynthesis of 4-[(2-chloroethyl)(2-[(11)C]ethyl)amino]-phenoxycarbonyl-l-glutamic acid a half mustard prodrug as a potential probe for imaging antibody- and gene-directed enzyme prodrug therapy with positron emission tomography. Appl Radiat Isot. 60:825-834. DOI.
  • Kenny LM; Aboagye EO; Price PM. (May 2004). Positron emission tomography imaging of cell proliferation in oncology. Clin Oncol (R Coll Radiol). 16:176-185.
  • Groot-Wassink T; Aboagye EO; Wang Y; Lemoine NR; Reader AJ; Vassaux G. (Mar 2004). Quantitative imaging of Na/I symporter transgene expression using positron emission tomography in the living animal. Mol Ther. 9:436-442. DOI.
  • Barthel H; Price P; Aboagye EO. (Feb 2004). Advances in research - Small-animal imaging of tumour proliferation with PET. LANCET ONCOL. 5:100-100.
  • Barthel H; Price P; Aboagye EO. (Feb 2004). Small-animal imaging of tumour proliferation with PET. Lancet Oncol. 5:100. DOI.
  • Collingridge DR; Glaser M; Osman S; Barthel H; Hutchinson OC; Luthra SK; Brady F; Bouchier-Hayes L; et al. (6 Oct 2003). In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotope. Br J Cancer. 89:1327-1333. DOI.
  • Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; et al. (1 Jul 2003). 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res. 63:3791-3798.
  • Saleem A; Brown GD; Brady F; Aboagye EO; Osman S; Luthra SK; Ranicar AS; Brock CS; et al. (15 May 2003). Metabolic activation of temozolomide measured in vivo using positron emission tomography. Cancer Res. 63:2409-2415.
  • Wells P; Aboagye E; Gunn RN; Osman S; Boddy AV; Taylor GA; Rafi I; Hughes AN; et al. (7 May 2003). 2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337. J Natl Cancer Inst. 95:675-682.
  • Aboagye EO; Price PM. (May 2003). Use of positron emission tomography in anticancer drug development. Invest New Drugs. 21:169-181.
  • Propper DJ; de Bono J; Saleem A; Ellard S; Flanagan E; Paul J; Ganesan TS; Talbot DC; et al. (15 Jan 2003). Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000. J Clin Oncol. 21:203-210.
  • Glaser M; Collingridge DR; Aboagye EO; Bouchier-Hayes L; Hutchinson OC; Martin SJ; Price P; Brady F; et al. (Jan 2003). Iodine-124 labelled annexin-V as a potential radiotracer to study apoptosis using positron emission tomography. Appl Radiat Isot. 58:55-62.
  • Hutchinson OC; Collingridge DR; Barthel H; Price PM; Aboagye EO. (2003). Pharmacodynamics of radiolabelled anticancer drugs for positron emission tomography. Curr Pharm Des. 9:931-944.
  • Hutchinson OC; Collingridge DR; Barthel H; Price PM; Aboagye EO. (2003). Pharmacokinetics of radiolabelled anticancer drugs for positron emission tomography. Curr Pharm Des. 9:917-929.
  • Gupta N; Price PM; Aboagye EO. (Nov 2002). PET for in vivo pharmacokinetic and pharmacodynamic measurements. Eur J Cancer. 38:2094-2107.
  • Collingridge DR; Carroll VA; Glaser M; Aboagye EO; Osman S; Hutchinson OC; Barthel H; Luthra SK; et al. (15 Oct 2002). The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res. 62:5912-5919.
  • Liu D; Hutchinson OC; Osman S; Price P; Workman P; Aboagye EO. (23 Sep 2002). Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin. Br J Cancer. 87:783-789. DOI.
  • Groot-Wassink T; Aboagye EO; Glaser M; Lemoine NR; Vassaux G. (20 Sep 2002). Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum Gene Ther. 13:1723-1735. DOI.
  • Aboagye E. (1 Jul 2002). The use of imaging to accelerate drug development. Drug Discov Today. 7:706-707.
  • Gupta N; Saleem A; Osman S; Hoskin P; Price PM; Aboagye EO. (Jun 2002). Carbogen and nicotinamide selectively increase chemotherapy delivery and blood flow to liver metastasis. BRIT J CANCER. 86:S14-S14.
  • Yau K; Price P; Aboagye EO. (Jun 2002). Detection of thymidylate synthase (TS) inhibition. BRIT J CANCER. 86:S110-S110.
  • Barthel H; Brown G; Wilson H; Collingridge DR; Price PM; Aboagye EO. (Jun 2002). In vivo evaluation of [F-18]fluoroetanidazole for imaging tumour hypoxia with positron emission tomography (PET). BRIT J CANCER. 86:S13-S13.
  • Barthel H; Cleji MC; Collingridge DR; Osman S; Brady F; Luthra SK; Price PM; Aboagye EO. (May 2002). In vivo evaluation of F-18-FLT for monitoring drug-induced modulation of tumor proliferation with positron emission tomography. J NUCL MED. 43:27P-27P.
  • Aboagye EO; Luthra SK; Brady F; Poole K; Anderson H; Jones T; Boobis A; Burtles SS; et al. (8 Apr 2002). Cancer Research UK procedures in manufacture and toxicology of radiotracers intended for pre-phase I positron emission tomography studies in cancer patients. Br J Cancer. 86:1052-1056. DOI.
  • Brady F; Luthra SK; Brown GD; Osman S; Aboagye E; Saleem A; Price PM. (Dec 2001). Radiolabelled tracers and anticancer drugs for assessment of therapeutic efficacy using PET. Curr Pharm Des. 7:1863-1892.
  • Aboagye EO. (Jul 2001). Development of molecular imaging paradigms. BRIT J CANCER. 85:14-14.
  • Aboagye EO; Saleem A; Cunningham VJ; Osman S; Price PM. (1 Jul 2001). Extraction of 5-fluorouracil by tumor and liver: a noninvasive positron emission tomography study of patients with gastrointestinal cancer. Cancer Res. 61:4937-4941.
  • Hutchinson OC; Liu D; Osman S; Price P; Workman P; Aboagye EO. (Jul 2001). Use of C-14 methyl choline to monitor inhibition of the extracellular signal-regulated kinase cascade: A novel approach towards imaging of signal-transduction inhibition. BRIT J CANCER. 85:89-89.
  • Pilatus U; Aboagye E; Artemov D; Mori N; Ackerstaff E; Bhujwalla ZM. (May 2001). Real-time measurements of cellular oxygen consumption, pH, and energy metabolism using nuclear magnetic resonance spectroscopy. Magn Reson Med. 45:749-755.
  • Osman S; Rowlinson-Busza G; Luthra SK; Aboagye EO; Brown GD; Brady F; Myers R; Gamage SA; et al. (1 Apr 2001). Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide and DNA-intercalating analogues. Cancer Res. 61:2935-2944.
  • Aboagye EO; Price PM; Jones T. (15 Mar 2001). In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography. DRUG DISCOV TODAY. 6:293-302.
  • Saleem A; Harte RJ; Matthews JC; Osman S; Brady F; Luthra SK; Brown GD; Bleehen N; et al. (1 Mar 2001). Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography. J Clin Oncol. 19:1421-1429.
  • Aboagye EO; Mori N; Bhujwalla ZM. (2001). Effect of malignant transformation on lactate levels of human mammary epithelial cells. Adv Enzyme Regul. 41:251-260.
  • Bhujwalla ZM; Artemov D; Aboagye E; Ackerstaff E; Gillies RJ; Natarajan K; Solaiyappan M. (2001). The physiological environment in cancer vascularization, invasion and metastasis. Novartis Found Symp. 240:23-38.
  • Saleem A; Yap J; Osman S; Brady F; Suttle B; Lucas SV; Jones T; Price PM; et al. (17 Jun 2000). Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. Lancet. 355:2125-2131.
  • Saleem A; Aboagye EO; Price PM. (15 Mar 2000). In vivo monitoring of drugs using radiotracer techniques. Adv Drug Deliv Rev. 41:21-39.
  • Natarajan K; Mori N; Artemov D; Aboagye EO; Chacko VP; Bhujwalla ZM. (2000). Phospholipid profiles of invasive human breast cancer cells are altered towards a less invasive phospholipid profile by the anti-inflammatory agent indomethacin. Adv Enzyme Regul. 40:271-284.
  • Aboagye EO. (Nov 1999). Cancer Research Campaign's (CRC) program of in vivo pharmacokinetics and pharmacodynamics in drug development using positron emission tomography. CLIN CANCER RES. 5:3871S-3872S.
  • Bhujwalla ZM; Aboagye EO; Gillies RJ; Chacko VP; Mendola CE; Backer JM. (May 1999). Nm23-transfected MDA-MB-435 human breast carcinoma cells form tumors with altered phospholipid metabolism and pH: a 31P nuclear magnetic resonance study in vivo and in vitro. Magn Reson Med. 41:897-903.
  • Aboagye EO; Bhujwalla ZM. (1 Jan 1999). Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res. 59:80-84.
  • Aboagye EO; Kelson AB; Tracy M; Workman P. (Dec 1998). Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography (vol 13, pg 703, 1998). ANTI-CANCER DRUG DES. 13:1009-1010.
  • Aboagye EO; Artemov D; Senter PD; Bhujwalla ZM. (15 Sep 1998). Intratumoral conversion of 5-fluorocytosine to 5-fluorouracil by monoclonal antibody-cytosine deaminase conjugates: noninvasive detection of prodrug activation by magnetic resonance spectroscopy and spectroscopic imaging. Cancer Res. 58:4075-4078.
  • Aboagye EO; Kelson AB; Tracy M; Workman P. (Sep 1998). Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography. Anticancer Drug Des. 13:703-730.
  • Aboagye EO; Bhujwalla ZM; Shungu DC; Glickson JD. (1 Jul 1998). Detection of tumor response to chemotherapy by H-1 nuclear magnetic resonance spectroscopy: Effect of 5-fluorouracil on lactate levels in radiation-inducted fibrosarcoma 1 tumors (vol 58, pg 1063, 1998). CANCER RES. 58:2904-2904.
  • Aboagye EO; Bhujwalla ZM; He Q; Glickson JD. (Jul 1998). Evaluation of lactate as a 1H nuclear magnetic resonance spectroscopy index for noninvasive prediction and early detection of tumor response to radiation therapy in EMT6 tumors. Radiat Res. 150:38-42.
  • McSheehy PM; Robinson SP; Ojugo AS; Aboagye EO; Cannell MB; Leach MO; Judson IR; Griffiths JR. (15 Mar 1998). Carbogen breathing increases 5-fluorouracil uptake and cytotoxicity in hypoxic murine RIF-1 tumors: a magnetic resonance study in vivo. Cancer Res. 58:1185-1194.
  • Aboagye EO; Bhujwalla ZM; Shungu DC; Glickson JD. (1 Mar 1998). Detection of tumor response to chemotherapy by 1H nuclear magnetic resonance spectroscopy: effect of 5-fluorouracil on lactate levels in radiation-induced fibrosarcoma 1 tumors. Cancer Res. 58:1063-1067.
  • Aboagye EO; Dillehay LE; Bhujwalla ZM; Lee DJ. (1998). Hypoxic cell cytotoxin tirapazamine induces acute changes in tumor energy metabolism and pH: a 31P magnetic resonance spectroscopy study. Radiat Oncol Investig. 6:249-254. DOI.
  • Aboagye EO; Maxwell RJ; Horsman MR; Lewis AD; Workman P; Tracy M; Griffiths JR. (1998). The relationship between tumour oxygenation determined by oxygen electrode measurements and magnetic resonance spectroscopy of the fluorinated 2-nitroimidazole SR-4554. Br J Cancer. 77:65-70.
  • Aboagye EO; Lewis AD; Tracy M; Workman P. (1 Dec 1997). Bioreductive metabolism of the novel fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitroimidazolyl) acetamide (SR-4554). Biochem Pharmacol. 54:1217-1224.
  • Aboagye EO; Maxwell RJ; Kelson AB; Tracy M; Lewis AD; Graham MA; Horsman MR; Griffiths JR; et al. (1 Aug 1997). Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxia. Cancer Res. 57:3314-3318.
  • Aboagye EO; Lewis AD; Graham MA; Tracy M; Kelson AB; Ryan KJ; Workman P. (Apr 1996). The pharmacokinetics, bioavailability and biodistribution in mice of a rationally designed 2-nitroimidazole hypoxia probe SR-4554. Anticancer Drug Des. 11:231-242.
  • Aboagye EO; Graham MA; Lewis AD; Workman P; Kelson AB; Tracy M. (6 Oct 1995). Development and validation of a solid-phase extraction and high-performance liquid chromatographic assay for a novel fluorinated 2-nitroimidazole hypoxia probe (SR-4554) in Balb/c mouse plasma. J Chromatogr B Biomed Appl. 672:125-132.
  • Aboagye EO; Lewis AD; Johnson A; Workman P; Tracy M; Huxham IM. (Aug 1995). The novel fluorinated 2-nitroimidazole hypoxia probe SR-4554: reductive metabolism and semiquantitative localisation in human ovarian cancer multicellular spheroids as measured by electron energy loss spectroscopic analysis. Br J Cancer. 72:312-318.

Chapters in books

  • Aboagye EO; Saleem A; Price PM. Tumor imaging applications in the testing of new drugs. In Anticancer drug development. 353-369. (2002).

Conferences

  • Walledge RJ; Reader AJ; Aboagye EO; Spinks TJ; Honer M; Missimer J; Jeavons AP. 4D PET with the quad-HIDAC: Development of dynamic list-mode EM image reconstruction. IEEE Nuclear Science Symposium/Medical Imaging Conference (NSS/MIC), 10 Nov 2002 - 16 Nov 2002. 1716-1720. IEEE (2003).
  • Aboagye EO; Salaam A; Gupta N; Brock C; Price P. What new pharmacokinetic information can molecular imaging provide us. 14th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics. 38:S12-S12. (Nov 2002).
  • Kenny LM; Al-Nahhas A; Vigushin D; Coombes RC; Aboagye EO. [F-18]Fluorothymidine retention in breast cancer measured by PET - Initial results from a pilot study. Annual Congress of the European-Association-of-Nuclear-Medicine. 31:S328-S328. (Aug 2004).
  • Kenny LM; Aboagye EO; Al-Nahhas A; Charles L; Coombes RC. [C-11]choline-PET in human breast cancer: utility, reproducibility and effect of receptor tyrosine kinase inhibition by trastuzumab. 29th Annual San Antonio Breast Cancer Symposium. 100:S212-S212. (Jan 2006).
  • Kenny L; Al-Nahhas A; Shousha S; Osman S; Vigushin DM; Coombes RC; Aboagye EO. Determination of [F-18]fluorothymidine kinetics in tumour and normal tissues of patients with breast cancer using positron emission tomography. British Cancer Research Meeting 2004, 27 Jun 2004 - 30 Jun 2004. 91:S44-S44. NATURE PUBLISHING GROUP (Jul 2004).
Social Bookmarking:
Delicious
Digg